Safety and Efficacy of Tocilizumab in the Treatment of Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia: A Retrospective Cohort Study

Background: Cytokine release storm (CRS) in severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) is thought to be the cause for organ damage and death which is independent of the actual viral burden. Tocilizumab (TCZ), an interleukin-6 receptor antagonist, is approved for the treatment of CR...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Atul, Shah, Kinjal, Dharsandiya, Mitkumar, Patel, Ketan, Patel, Tushar, Patel, Mukesh, Reljic, Tea, Kumar, Ambuj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Indian Journal of Medical Microbiology. Published by Elsevier B.V. 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7706820/
https://www.ncbi.nlm.nih.gov/pubmed/32719218
http://dx.doi.org/10.4103/ijmm.IJMM_20_298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7706820/
https://www.ncbi.nlm.nih.gov/pubmed/32719218
http://dx.doi.org/10.4103/ijmm.IJMM_20_298

Ejemplares similares